Eli Lilly & Co.'s average net prices across its US product portfolio increased 6% in 2017 despite significant rebates and discounts, according to drug pricing data in the company's recently-released Integrated Summary Report.
Discounts and rebates collectively reduced list prices by an average of 51% in 2017, up slightly from 50% in 2016....